Current investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating promising results in managing excess mass and related non-insulin-dependent diabetes. Preclinical data suggest a https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/